Cargando…

Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia

Neuropeptide S (NPS) is a factor associated with the central regulation of body weight, stress, anxiety, learning, memory consolidation, wakefulness–sleep cycle, and anti-inflammatory and neuroplastic effects. Its stress-reducing, anti-anxiety, arousal without anxiety, and pro-cognitive effects repr...

Descripción completa

Detalles Bibliográficos
Autores principales: Markiewicz-Gospodarek, Agnieszka, Markiewicz, Renata, Dobrowolska, Beata, Maciejewski, Ryszard, Łoza, Bartosz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221542/
https://www.ncbi.nlm.nih.gov/pubmed/35741653
http://dx.doi.org/10.3390/brainsci12060768
_version_ 1784732649116401664
author Markiewicz-Gospodarek, Agnieszka
Markiewicz, Renata
Dobrowolska, Beata
Maciejewski, Ryszard
Łoza, Bartosz
author_facet Markiewicz-Gospodarek, Agnieszka
Markiewicz, Renata
Dobrowolska, Beata
Maciejewski, Ryszard
Łoza, Bartosz
author_sort Markiewicz-Gospodarek, Agnieszka
collection PubMed
description Neuropeptide S (NPS) is a factor associated with the central regulation of body weight, stress, anxiety, learning, memory consolidation, wakefulness–sleep cycle, and anti-inflammatory and neuroplastic effects. Its stress-reducing, anti-anxiety, arousal without anxiety, and pro-cognitive effects represent an interesting option for the treatment of neuropsychiatric disorders. The purpose of the study was to examine the potential associations of NPS levels in the blood with clinical and metabolic parameters during the rehabilitation therapy of patients with schizophrenia. Thirty-three male subjects diagnosed with schizophrenia were randomly divided into two groups. The rehabilitation group (REH, N16) consisted of patients who were subjected to structured, 3-month intensive rehabilitation therapy, and the control group (CON, N17) consisted of patients who were subjected to a standard support mechanism. Both groups continued their pharmacological treatment as usual. The NPS concentration, as well as clinical and metabolic parameters, were compared in both groups. Additionally, a group of healthy (H) males (N15) was tested for NPS reference scores. To look for the specificity and selectivity of the NPS relationship with clinical results, various factor models of the positive and negative syndrome scale (PANSS) were analyzed, including the original PANSS 2/3 model, its modified four-factor version, the male-specific four-factor model, and two five-factorial models validated in large groups in clinical and multi-ethnic studies. Results and conclusions: (1) Structured rehabilitation therapy, compared to unstructured supportive therapy, significantly reduced the level of schizophrenia disorders defined by various factor models derived from PANSS. (2) The clinical improvement within the 3-month rehabilitation therapy course was correlated with a significant decrease in neuropeptide S (NPS) serum level. (3) The excitement/Hostility (E/H) factor, which included schizophrenic symptoms of the psychotic disorganization, was specific and selective for the reduction in serum NPS, which was stable across all analyzed factor models. (4) The long-term relationship between serum NPS and clinical factors was not accompanied by basic metabolic parameters.
format Online
Article
Text
id pubmed-9221542
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92215422022-06-24 Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia Markiewicz-Gospodarek, Agnieszka Markiewicz, Renata Dobrowolska, Beata Maciejewski, Ryszard Łoza, Bartosz Brain Sci Article Neuropeptide S (NPS) is a factor associated with the central regulation of body weight, stress, anxiety, learning, memory consolidation, wakefulness–sleep cycle, and anti-inflammatory and neuroplastic effects. Its stress-reducing, anti-anxiety, arousal without anxiety, and pro-cognitive effects represent an interesting option for the treatment of neuropsychiatric disorders. The purpose of the study was to examine the potential associations of NPS levels in the blood with clinical and metabolic parameters during the rehabilitation therapy of patients with schizophrenia. Thirty-three male subjects diagnosed with schizophrenia were randomly divided into two groups. The rehabilitation group (REH, N16) consisted of patients who were subjected to structured, 3-month intensive rehabilitation therapy, and the control group (CON, N17) consisted of patients who were subjected to a standard support mechanism. Both groups continued their pharmacological treatment as usual. The NPS concentration, as well as clinical and metabolic parameters, were compared in both groups. Additionally, a group of healthy (H) males (N15) was tested for NPS reference scores. To look for the specificity and selectivity of the NPS relationship with clinical results, various factor models of the positive and negative syndrome scale (PANSS) were analyzed, including the original PANSS 2/3 model, its modified four-factor version, the male-specific four-factor model, and two five-factorial models validated in large groups in clinical and multi-ethnic studies. Results and conclusions: (1) Structured rehabilitation therapy, compared to unstructured supportive therapy, significantly reduced the level of schizophrenia disorders defined by various factor models derived from PANSS. (2) The clinical improvement within the 3-month rehabilitation therapy course was correlated with a significant decrease in neuropeptide S (NPS) serum level. (3) The excitement/Hostility (E/H) factor, which included schizophrenic symptoms of the psychotic disorganization, was specific and selective for the reduction in serum NPS, which was stable across all analyzed factor models. (4) The long-term relationship between serum NPS and clinical factors was not accompanied by basic metabolic parameters. MDPI 2022-06-11 /pmc/articles/PMC9221542/ /pubmed/35741653 http://dx.doi.org/10.3390/brainsci12060768 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Markiewicz-Gospodarek, Agnieszka
Markiewicz, Renata
Dobrowolska, Beata
Maciejewski, Ryszard
Łoza, Bartosz
Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia
title Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia
title_full Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia
title_fullStr Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia
title_full_unstemmed Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia
title_short Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia
title_sort relationship of neuropeptide s with clinical and metabolic parameters of patients during rehabilitation therapy for schizophrenia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221542/
https://www.ncbi.nlm.nih.gov/pubmed/35741653
http://dx.doi.org/10.3390/brainsci12060768
work_keys_str_mv AT markiewiczgospodarekagnieszka relationshipofneuropeptideswithclinicalandmetabolicparametersofpatientsduringrehabilitationtherapyforschizophrenia
AT markiewiczrenata relationshipofneuropeptideswithclinicalandmetabolicparametersofpatientsduringrehabilitationtherapyforschizophrenia
AT dobrowolskabeata relationshipofneuropeptideswithclinicalandmetabolicparametersofpatientsduringrehabilitationtherapyforschizophrenia
AT maciejewskiryszard relationshipofneuropeptideswithclinicalandmetabolicparametersofpatientsduringrehabilitationtherapyforschizophrenia
AT łozabartosz relationshipofneuropeptideswithclinicalandmetabolicparametersofpatientsduringrehabilitationtherapyforschizophrenia